6.5 Effects on cardiovascular outcomes The effects of tirzepatide on cardio metabolic risk factors and vascular consequences have been investigated in the context of the SURPASS trials
Working With Healthcare Providers For Canadian patients pursuing FDA-approved medications once Retatrutide receives approval, the process typically involves initial consultation to establish obesity diagnosis and discuss treatment options, baseline laboratory work including metabolic panel, lipid profile, and A1C if diabetic, discussion of contraindications and potential drug interactions, prescription and prior authorization if required by insurance, and scheduled follow-up appointments for monitoring
While not yet approved for medical use, the peptide is sold for research purposes and research applications, demonstrating intriguing outcomes in animals, SD rats, and early human observations
This was demonstrated through bioequivalence studies and supported by the broader semaglutide clinical trial program